OncoMatch/Clinical Trials/NCT06855810
Newly-diagnosed Pediatric T-cell ALL Protocol
Is NCT06855810 recruiting? Yes, currently enrolling (May 2026). This Phase 2/3 trial studies multiple treatments including Venetoclax and Dasatinib for acute lymphoblastic leukemia.
Treatment: Venetoclax · Dasatinib · homoharringtonine — This is a prospective, multicenter study conducted within the Chinese Children's Cancer Group (CCCG). The study aims to evaluate whether the addition of three novel agents, dasatinib, venetoclax and homoharringtonine, can improve the minimal residual disease (MRD)-negative remission rate, enhance event-free survival (EFS), and reduce the cumulative incidence of relapse (CIR) in pediatric patients with newly diagnosed T-cell acute lymphoblastic leukemia (T-ALL).
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Prior therapy
Cannot have received: glucocorticoid
Treated with glucocorticoids for ≥14 days within one month before enrollment
Cannot have received: ABL kinase inhibitor
Treated with ABL kinase inhibitors for > 7 days within one month before enrollment
Cannot have received: chemotherapy
Exception: except for emergency radiotherapy to relieve airway compression
any chemotherapy or radiotherapy within 3 months before enrollment (except for emergency radiotherapy to relieve airway compression)
Cannot have received: radiation therapy
Exception: except for emergency radiotherapy to relieve airway compression
any chemotherapy or radiotherapy within 3 months before enrollment (except for emergency radiotherapy to relieve airway compression)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify